KUALA LUMPUR, Malaysia--(BUSINESS WIRE)-- SLB (NYSE: SLB) today announced results for the first-quarter 2024. This press release features multimedia. View the full release here: The exterior of the SLB headquarters in Houston, Texas (Photo: Business Wire) First-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31,2024 Dec. 31,2023 Mar. 31,2023 Sequential Year-on-year Revenue $8,707 $8,990 $7,736 -3% 13% Income before taxes - GAAP basis $1,357 $1,433 $1,161 ...
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company'...
Intra-Cellular Therapies Prices Public Offering of Common Stock NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to I...
Ingredion to Release 2024 First Quarter Financial Results on May 8, 2024 WESTCHESTER, Ill., April 17, 2024 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food manufacturing industry, will release its 2024 first quarter financial results for the period ended March 31, 2024, before the market opens Wednesday, May 8, 2024. , president and chief executive officer and , executive vice president and chief financial officer, will host a conference call May 8 at 8 a.m. CT to discuss the Company's financial performance. The confer...
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% ...
GULFPORT, Miss.--(BUSINESS WIRE)-- (Nasdaq: HWC) today announced its financial results for the first quarter of 2024. Net income for the first quarter of 2024 totaled $108.6 million, or $1.24 per diluted common share (EPS), compared to $50.6 million, or $0.58 per diluted common share, in the fourth quarter of 2023. The first quarter of 2024 included a $3.8 million charge, or $0.04 per diluted common share, of a supplemental disclosure item, related to a revision to the FDIC Special Assessment. The fourth quarter of 2023 included a net charge of $75.4 million, or $0.68 per diluted share after-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.